As a consequence, AKT is considered as a target for cancer research and therapeutic development.408,409 In 2020, Toker et al. constructed an AKT degrader, INY-03-041, consisting of the pan-AKT inhibitor GDC-0068 conjugated to lenalidomide. Here, AKT1 is linked to cancer.